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Abstract
Objective: the aim was to identify in 511 outpatients, with diagnoses of schizophrenia, major 
depressive disorder (MDD), bipolar disorders (BD), and borderline personality disorder (BPD), 
what clinical variables predict the improvement of real-world functioning during 12 months 
of usual treatment.
Methods: sociodemographic variables were evaluated. Patients were assessed at baseline and 
endpoint with: Clinical Global Impression Scale - Severity (CGI-S); Satisfaction Profile (SAT-P), 
Drug Attitude Inventory-10 (DAI-10), and Personal and Social Performance (PSP). Statistical 
analysis was performed with Chi-square test and Pearson’s correlation. Significant variables 
were included in a multiple regression analysis. Dependent variable was the difference of PSP 
after one year (ΔPSP). P ≤ 0.05 was significant.
Results: in the total sample, ΔPSP was related to age of onset, SAT-P and psychotherapy 
and inversely related to suicide attempts and CGI-S. In schizophrenia, ΔPSP was related to 
SAT-P and DAI-10 and inversely related to CGI-S. In MDD, ΔPSP was related to SAT-P and 
psychotherapy and inversely related to suicide attempts and CGI-S. In BD, ΔPSP was related to 
SAT-P and inversely related to CGI-S. In BPD, only psychotherapy was related to ΔPSP.
Conclusion: Symptoms severity predicted a worse community functioning in the total 
sample and in each group, except for BPD. Suicide attempts were inversely associated to 
functional improvement in the total sample and depression. Quality of life was related to the 
change of functioning in each group, except for BPD. Patients with MMD and BPD receiving 
psychotherapy gained a better functional improvement. Attitude to pharmacotherapy was 
related to functional improvement only in schizophrenia.
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Introduction
Real life disability produced by mental illness 
is responsible for the considerable costs of 
psychiatric disturbances in terms of expensive 
medical care and lost days at work. In the last 
years, after obtaining significant results in 
treating symptoms of mental disorders, authors 
focused their investigations on the real-world 
functioning of severe psychiatric patients. 
The everyday performance includes general 
organization, communication skills, finance 
management, independent living, medication 
management, and social interactions. With 
regard to this concept, there is a core distinction 
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concepts are partly different from that of real-
world functioning that measures the actual 
performance obtained in everyday context and 
combines the patient’s functional capacity 
with the real opportunities available in the 
environment. 
The present study is a naturalistic investigation 
aimed to identify in a sample of outpatients, 
including patients with schizophrenia; bipolar 
disorders; major depressive disorder, and 
borderline personality disorder, whether 
different variables, including psychiatric 
symptoms, onset and duration of illness, attitude 
to treatments, type of treatment and subjective 
quality of life may predict a change of the real-
world functioning.
Methods
This study was conducted on 511 outpatients 
who attended the Psychiatric Clinic of the 
Department of Neuroscience of the University 
of Turin and completed a period of 12 months 
of usual treatment. They were recruited between 
June 2015 and May 2016. Inclusion criteria were 
a diagnosis of: 1) major depressive disorder; 2) 
bipolar disorders; 3) schizophrenia; 4) borderline 
personality disorder, according to DSM-5, and 
an age ranged between 18 and 60 years. Exclusion 
criteria were: a lifetime diagnosis of delirium, 
major and mild neurocognitive disorders. 
Diagnoses were made by an expert clinician and 
were confirmed using the Structured Clinical 
Interview for DSM-IV Axis I or II disorders 
[20,21]. 
All subjects were submitted to standard care, 
provided in community mental health centers 
in Italy, including pharmacological treatments 
as recommended by the guidelines, clinical 
monitoring at least on a monthly basis, and 
psychological interventions for selected patients. 
In particular, the two groups of patients 
with major depressive disorder (MDD) and 
borderline personality disorder (BPD) were 
treated with interpersonal psychotherapy. 
Subjects with MDD received traditional IPT 
lasting 16 weeks (International Society of 
Interpersonal Psychotherapy - isIPT, www.
interpersonalpsychotherapy.org), while BPD 
patients received the adaptation of IPT to BPD 
(IPT-BPD), lasting 40 weeks [22]. Patients in the 
other two diagnostic categories (schizophrenia 
and bipolar disorder) were not treated with 
psychotherapy in our study.
between functional capacity (the ability to 
obtain a good level of functioning under 
optimal conditions) and real-world functioning 
(the patient’s actual performance when he has 
to face the real circumstances of his life and 
environment) [1]. 
Initial studies in this field were performed in 
patients with a diagnosis of schizophrenia, a 
major psychiatric disturbance inducing a high 
degree of impairment in main areas of everyday 
life (independent living, employment, marital 
status, and social relationships) [2-4]. Several 
studies aimed to identify the predictive factors 
of functioning concluded that the achievement 
of the real-life functional milestones, such as 
educational level, independence in housing, 
current work situation, marital status, and 
quantity and quality of social contacts, depends 
on different variables, related to the characteristics 
of the disorders, the individual resources, and the 
context of patient’s life [5-8]. 
In more recent years studies on this topic 
were extended to other mental disorders, in 
particular bipolar disorder (BP). Because of 
the chronic course of BP patients showed a 
rate of achievement of functional milestones 
significantly lower than general population 
[9,10]. Main findings suggested that mood 
symptoms and illness characteristics had a 
significant impact on a broad range of everyday 
expressions of functioning. Impaired community 
functioning has been reported in all phases of 
illness, including periods of euthymia [11,12]. 
In addition, authors found that episodes of 
depression are more detrimental to real-life 
functioning than mania [13]. In particular, 
attitudes such as giving up and self-blame are 
significant predictors of real-world functioning 
beyond sub-threshold depressive symptoms [14].
Only one systematic review is available on 
assessment of real-world functioning in patients 
with major depressive disorder (MDD) [15]. 
Authors evaluated the negative impact of major 
depression on quality of life, disability, work, 
family, and general psychosocial functioning. 
They concluded that depressive symptoms 
negatively affect real-life functioning and that the 
impairment of quality of life and functioning at 
baseline is significantly related to poor treatment 
outcome [15-17]. 
At the moment, a few authors [18,19] have 
investigated in samples of patients with severe 
personality disorders concepts such as social 
and occupational functioning. However, these 
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The study was approved by the Ethical 
Committee of our University Hospital. Written 
informed consent was obtained from all patients 
prior to their participation. Declaration of 
Helsinki guidelines were followed.
At baseline, a series of sociodemographic 
variables were evaluated with a semi-structured 
interview.
Categorical variables were recorded as “yes/
no” and included: gender (male/female), 
positive psychiatric anamnesis (previous request 
of psychiatric assistance/treatment), suicide 
attempts, treatment with antipsychotics, 
mood stabilizers, antidepressants, and/or 
psychotherapy. Treatment with medications 
was recorded asking directly to the patients and 
caregivers what they had been taking. 
Continuous variables included age (years), age 
at onset (age of first psychiatric visit), education 
(years at school), and illness duration (years from 
the first psychiatric visit).
Patients were assessed at baseline with the 
following instruments: the severity item of the 
Clinical Global Impression Scale (CGI-S) [23]; 
the Personal and Social Performance (PSP) [24]; 
the Satisfaction Profile (SAT-P) [25]; and the 
Drug Attitude Inventory-10 (DAI-10) [26]. The 
same instruments were re-administered after 12 
months of usual care.
The CGI is a clinician-rated instrument to make 
global assessment of illness and consists of three 
different measures: severity of illness, global 
improvement, and efficacy index (comparison 
between patient’s baseline condition and a ratio 
of current therapeutic benefit and severity of 
side effects). In this study, we considered the 
first scale: severity of illness. It is a 7-point scale 
that requires the clinician to rate the severity 
of illness at the time of assessment: (1) normal, 
(2), borderline mentally ill, (3) mildly ill, (4) 
moderately ill, (5) markedly ill, (6) severely ill, 
(7) extremely ill.
The PSP is a clinician-rated scale to assess the 
real-world functioning in patients with a variety 
of psychiatric conditions. This instrument 
was developed from Social and Occupational 
Functioning Assessment Scale - SOFAS [27]. 
PSP measures social functioning within four 
domains: (1) socially useful activities; (2) 
personal and social relationships; (3) self-care; 
and (4) disturbing and aggressive behaviours. 
The score is ranged between 1 and 100. Higher 
score is linked to better functioning.
The SAT- P is a self-administered questionnaire 
consisting of 32 scales which provides a 
satisfaction profile in daily life and can be 
considered as an indicator of subjective quality of 
life. The SAT-P considers five different factors: 
(1) psychological functioning; (2) physical 
functioning; (3) work; (4 ) sleep; (5) food, and 
(6) free time; (7) social functioning. The SAT-P 
asks the patient to evaluate his satisfaction in the 
last month for each of the 32 life aspects on a 
scale ranging from “extremely dissatisfied” (0) 
to “extremely satisfied” (100). The score used in 
this study is the “factors-related score”. For each 
factor was attributed a score range between 0 and 
100.
The DAI-10 is the short-version of the DAI-
30. It is a self-report scale measuring patients’ 
subjective response and attitude toward drugs 
therapy. The DAI-10 scoring ranges from -10 to 
+10 with a total score >0 indicating a positive 
attitude toward psychiatric medications and a 
total score of <0 indicating a negative attitude 
toward psychiatric medications.
Attainment in functional milestones were 
recorded as follows: (1) employment status 
(employed/not employed); (2) residential 
status (independent/dependent); (3) marital 
status/stable relationships (married/separated/
divorced subjects or individuals with long-
term relationship or equivalent versus not 
married patients or subjects without long-term 
relationship or equivalent).
Statistical analysis was performed using the 
software Statistical Package for the Social 
Sciences, SPSS, version 22 for Windows 
(SPSS, Chicago, IL, USA). Chi-square test for 
categorical variables and Pearson’s correlation for 
continuous variables were performed. Pearson’s 
correlation between the following continuous 
variables and change of PSP score were calculated: 
age, level of education, age of illness onset, 
duration of illness, number of hospitalizations, 
drug attitude (DAI-10 score), level of global 
symptoms (CGI-S score), subjective perception 
of quality of life (SAT-P score). The following 
categorical variables were evaluated with the 
chi-square test: gender, positive psychiatric 
anamnesis, psychiatric diagnosis, record of 
suicide attempts, use of antipsychotics; use of 
antidepressants, use of mood stabilizers, and 
ongoing psychotherapies.
All variables that were found significant were 
included in a multiple regression analysis 
(stepwise backward). Dependent variable was 
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the difference of PSP score between one year and 
baseline (ΔPSP).
At first time, bivariate analyses and multiple 
regression were performed in the whole sample 
of patients. Afterwards, analyses were repeated 
in each subsample of patients with diagnosis of 
schizophrenia; major depressive disorder; bipolar 
disorders; borderline personality disorder. 
Significance level was P ≤ 0.05.
Results
Among the 511 outpatients of our sample the 
diagnoses were distributed as following: 16.4% 
patients had a diagnosis of schizophrenia; 49.5% 
patients a diagnosis of major depressive disorder; 
17.6% patients of bipolar disorders, and 16.4% 
patients of borderline personality disorder. One 
hundred and eighty nine patients were male 
(36.98 %), the mean age was 50.99±16.41 (Mean 
±SD) years and the level of education was 11.28 
± 4.167 (Mean ±SD). Baseline characteristics 
of the total sample and of the four diagnostic 
groups are described in Table 1.
In the whole sample of 511 outpatients 
continuous variables that were found significant 
were: age of illness onset (r = 0.126; P = 0.007); 
DAI-10 (r = 0.212; P = 0.001); CGI-S (r = 
-0.109; P = 0.01); and SAT-P (r = 0.606; P = 
0.001). Significant categorical variables were: 
record of suicide attempts (χ2: -61.30; P = 
0.007); use of antipsychotics (χ2 = 54.81; P 
=0.03) and use of antidepressants (χ2 = 53.77; 
P = 0.04); and psychotherapy (χ2 = 118.742; P 
=0.001). 
All significant variables were included in a 
multiple regression analysis (stepwise backward). 
Change of PSP score was the dependent variable. 
Results showed that age of illness onset (P = 
0.009); SAT-P (P = 0.001); and psychotherapy 
(P = 0.001) were significantly and independently 
related to the change of PSP score. Record of 
suicide attempts (P = 0.02) and CGI-S (P = 
0.001) were inversely related to the change of 
PSP score.
In the subgroup of patients with schizophrenia, 
we found the following significant variables 
with Pearson’s correlation and Chi-square test: 
SAT-P (r = 0.659; P = 0.001), DAI-10 (r = 
0.774; P = 0.001), and CGI-S (r = -0.229; P 
= 0.036). All these variables were significantly 
and independently related to PSP change in the 
multiple regression analysis (respectively P = 
0.001, P = 0.001, and P = 0.02).
In the subsample of patients with major 
depressive disorder, we found the following 
significant variables with Pearson’s correlation 
and Chi-square test: age (r = -0.149; P = 0.02); 
DAI-10 (r = 0.267; P = 0.001); CGI-S (r 
= - 0.242; P = 0.001); SAT-P (r = 0.788; P = 
0.001); record of suicide attempts (χ2 = - 48.89; 
P = 0.03); use of mood stabilizers (χ2 = 50.56; 
P = 0.02); use of antidepressants (χ2 = 64.58; 
P =0.001); and psychotherapy (χ2 = 103.97; P 
= 0.001). Variables significantly related to PSP 
change with the multiple regression analysis 
were: SAT-P (P = 0.001) and psychotherapy (P 
= 0.001). Record of suicide attempts (P = 0.04) 
and CGI-S (P = 0.003) were inversely related to 
PSP change.
In the subgroup of patients with a diagnosis of 
bipolar disorders the following variables were 
found significant with Pearson’s correlation and 
Chi-square test: age of illness onset (r = 0.254; 
P = 0.02); duration of illness (r = -0.224; P = 
0.04); CGI-S (r = -0.489; P = 0.001); DAI-10 
(r = 0.398; P = 0.001); and SAT-P (r = 0.731; 
P = 0.001). Variable significantly related to PSP 
change with the multiple regression analysis 
was SAT-P (P = 0.001). CGI-S (P = 0.006) was 
inversely related to PSP improvement.
Finally, in the subgroup of patients with 
borderline personality disorder we found the 
following significant variables with Pearson’s 
correlation and Chi-square test: DAI-10 (r 
= 0.384; P = 0.001); CGI- S (r = -0.361; P = 
0.001); use of antidepressants (χ2 = 33.59; P 
= 0.04); and psychotherapy (χ2 = 81.23; P = 
0.001). Variable significantly related to PSP 
change with the multiple regression analysis was 
psychotherapy (P = 0.006).
Significant results of multiple regression analyses 
calculated in the total sample and in the four 
diagnostic groups are summarized in Table 2.
Discussion
Impairment in real-world functioning is a 
common feature of major psychiatric disorders. 
It is characterized by difficulties in achieving 
life milestones, including independent 
living, employment, and stable interpersonal 
relationships. Recent literature data suggested 
that several factors may influence the functional 
outcome in real world, in particular quality of 
life, adherence to treatments and severity of 
psychiatric symptoms [7,8,28,29]. The aim of 
the present study was to identify whether several 
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variables, including psychiatric symptoms, 
onset and duration of illness, hospitalizations, 
suicide attempts, attitude to treatments, 
pharmacotherapy, psychotherapy, and subjective 
perception of quality of life, are predictive of 
the change of the global measure of real-world 
functioning during one year of usual outpatient 
treatment in a large sample of subjects with a 
diagnosis of schizophrenia, bipolar disorders, 
major depression, or borderline personality 
disorder.
Previous investigations have been performed 
about the clinical and demographic predictive 
factors of real-world functioning in a single 
evaluation, but to our knowledge this is the first 
study that evaluated the relationship between 
these factors and the improvement of real-world 
functioning over a time span. Thus, our findings 
are only partially comparable with those of other 
trials.
The main results of our study showed that 
improvement of real-world functioning in the 
whole sample, measured with the change of 
PSP between baseline and one year of usual 
management, was directly and independently 
related to the age of illness onset, the subjective 
perception of quality of life, and the intervention 
with psychotherapy. On the other hand, the 
Table 1: Demographic and clinical variables in the whole sample of 511 outpatients and in the four subgroups: schizophrenia, 
major depressive disorder, bipolar disorder, and borderline personality disorder.
Variables Total sample SchizophreniaN = 84
MDD





Age (Mean ± SD) 50.99 ± 16.41 45.55 ± 16.65 54.43 ± 15.99 53.87 ± 13.91 43.02 ± 16.91
Age at onset (Mean ± SD) 39.47 ± 18.99 28.21 ± 9.96 44.61 ± 17.03 43.85 ± 24.64 31.64 ± 16.91
Education (Mean ± SD) 11.28 ± 4.17 10.71 ± 3.69 11.23 ± 4.21 10.91 ± 4.37 12.37 ± 4.14
Illness duration (Mean ± SD) 12.32 ± 12.68 16.65 ± 12.54 11.63 ± 13.76 12.87 ± 11 8.95 ± 10.59
CGI-S (Mean ± SD) 4.11 ± 1.06 5.23 ± 0.72 3.38 ± 0.63 4.32 ± 0.80 4.98 ± 0.88
PSP (Mean ± SD) 64.82 ± 11.01 58.11 ± 11.03 66.17 ± 9.29 66.84 ± 11.95 65.31 ± 12.36
DAI-10 (Mean ± SD) 2.03 ± 3.85 3.05 ± 4.56 4.37 ± 1.56 1.09 ± 2.47 2.66 ± 2.37
SAT-P (Mean ± SD) 60.37 ± 18.61 59.36 ± 19.43 67.98 ± 17.33 51.24 ± 16.96 48.24 ± 10.62
Male gender N (%) 189 (36.9) 39 (46.4) 77 (30.4) 35 (38.9) 38 (45.2)
Psych. anamnesis N (%) 392 (76.7) 80 (95.2) 165 (65.2) 79 (87.8) 68 (80.9)
Suicidal attempts N(%) 39 (7.63) 4 (4.7) 17 (6.7) 7 (7.8) 11 (13.1)
Antipsychotics N (%) 166 (32.5) 84 (100) 11 (4.3) 30 (33.3) 41 (48.8)
Mood stabilizers N (%) 157 (30.7) 19 (22.6) 9 (3.6) 87 (96.7) 61 (72.6)
Antidepressants N(%) 283 (55.4) 15 (11.9) 244 (96.4) 31 (34.4) 8 (9.5)
Psychotherapy N (%) 105 (20.5) 0 (0) 51 (20.2) 0 (0) 42 (50)
Diagnosis of schizophrenia N (%) 84 (16.4) -- -- -- --
Diagnosis of major depression N (%) 253 (49.5) -- -- -- --
Diagnosis of bipolar disorder N (%) 90 (17.6) -- -- -- --
Diagnosis of BPD N(%) 84 (16.4) -- -- -- --
N = number; MDD = Major Depressive Disorder; BP = Bipolar Disorder; BPD = Borderline Personality Disorder; DAI 10 = Drug Attitude Inventory-10; CGI – S 
= Clinical Global Impression- Severity; SAT- P = Satisfaction Profile; PSP = Personal and Social Performance.
Table 2: Results of multiple regression analysis in the whole sample of 511 patients and in the four subgroups: schizophrenia, 
major depressive disorder, bipolar disorder, and borderline personality disorder. Dependent variable ΔPSP. P ≤ 0.05 *; P ≤ 0.01 **
Variables Total sample        ß          SE
Schizophrenia 
ß         SE
MDD
ß        SE
BD
ß         SE
BPD
ß         SE
Suicidal 
attempts -2.39** 0.91 -- -- -2.04* 1.05 -- -- -- --
Age at onset 0.03** 0.01 -- -- -- -- -- -- -- --
CGI-S -1.54** 0.24 -1.16* 0.47 -1.27** 0.43 -2.45* 0.86 -- --
SAT-P 0.23** 0.01 0.09** 0.02 0.27** 0.02 0.34** 0.04 -- --
DAI-10 -- -- 0.72** 0.09 -- -- -- -- -- --
Psychotherapy 3.88** 0.54 -- -- 3.28** 0.59 -- -- 9.92** 0.96
MDD = Major Depressive Disorder; BP = Bipolar Disorder; BPD = Borderline Personality Disorder; DAI 10 = Drug Attitude 
Inventory-10; CGI – S = Clinical Global Impression- Severity; SAT- P = Satisfaction Profile; PSP = Personal and Social 
Performance¸ SE = Standard Error.
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severity of psychiatric symptoms and the presence 
of suicide attempts were inversely related to the 
change of PSP score and predicted a worse real-
world functioning. Concerning age at onset, 
literature findings are concordant with our data 
and indicate that patients with early-onset of 
disease have prominent deficits in functional 
outcome [30], probably due to the impact of 
the illness in a critical period of development, 
when specific social roles (such as independent 
living, work capacities, and secondary social 
relationships) and neurocognitive functions are 
still taking shape [31,32]. 
Several investigations have shown significant 
relations between patients’ functioning and 
quality of life, in terms of individual’s physical 
health status, psychological status and well-
being, and social interaction [33,34]. In 
particular, quality of life was found to be an 
important outcome indicator and predictor of 
symptomatic and functional improvement in 
schizophrenia [35]. Some authors, in line with 
our methodological choice, suggested that self-
reporting measures of quality of life are more 
appropriate than measures reported by clinicians 
[30,36,37]. Our findings are substantially in 
agreement with the previous studies outlining 
that improvement of real-world functional 
outcomes was significantly related to patients’ 
global life satisfaction [38], and better daily 
functioning is one of the indicator of recovery 
and better quality of life [39]. We found that a 
better subjective perception of quality of life was 
significantly related to PSP improvement in the 
whole sample of patients and in each diagnostic 
category, except for BPD. We can hypothesize 
that in BPD patients intense feelings of anger 
and dysphoria and persistent mood instability 
are likely to impair patients’ ability to appreciate 
and to take advantage in daily functioning from 
a better quality of life. 
In the present study, another important factor 
that was identified as a predictor of improvement 
of daily functioning, was a psychotherapeutic 
intervention. In fact, the two subgroups of 
patients with major depressive disorder and 
with borderline personality disorder, that were 
treated with interpersonal psychotherapy (IPT), 
showed a larger PSP change. Several previous 
investigations have shown that psychotherapies 
had positive effects in improving real-world 
functioning in psychiatric disorders [40-43]. 
In particular, interpersonal psychotherapy was 
found efficacious in improving the community 
interpersonal functioning in depressed patients 
[44,45]. Concerning BPD, limited research 
has focused on improvement of functional 
outcomes after psychotherapy. In fact, the 
majority of studies of specific psychotherapies 
for BPD patients were aimed to assess the 
efficacy of interventions in terms of decrease 
of symptoms severity [46,47]. Nevertheless, 
BPD patients have a high level of interpersonal 
reactivity and instability that produce a severe 
impairment in daily functioning [48]. So, it is 
not surprising that patients who receive IPT, a 
psychotherapeutic model specifically aimed at 
improving interpersonal functioning, present 
a significant overall improvement of daily 
functioning after one year.
In our investigation patients with a more 
severe degree of psychiatric symptoms showed 
a reduced daily functioning change during one 
year of usual treatment in the total sample and 
in each diagnostic category, again except for 
BPD. This finding is expected and intuitive as 
individuals with a higher level of symptoms 
producing a significant functional impairment 
have fewer resources to achieve and maintain 
the real-word milestones. Literature confirmed 
our results reporting significant relationships 
between severity of symptom domains and 
functional outcome in schizophrenia and 
mood disorders [49-57]. The lack of significant 
relationships between PSP change and severity of 
global symptoms in BPD patients might depend 
on the considerable heterogeneity of BPD 
symptomatology that would produce unstable 
and unpredictable effects on the real-world 
functioning.
As for the influence of suicidal behaviors on 
everyday functioning, a growing number of 
studies demonstrated that patients with a 
history of suicide attempts showed impaired 
functioning abilities [58], but no investigations 
have yet considered the impact of suicidality on 
the change of functioning level. In our study, 
we found that patients, with a higher number 
of suicide attempts, in particular subjects with a 
diagnosis of major depressive disorder, showed a 
lower degree of improvement in the community 
functioning. An interpretation of this result 
considers data indicating that patients with a 
history of suicidal acts present lower abilities in 
domains of neurocognitive functioning [58]. 
Thus, they show a reduced cognitive flexibility 
and a limited opportunity to change their real-
world daily-living skills.
In our investigation we also evaluated whether 
the attitude to pharmacotherapy may predict 
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the daily functioning improvement. Only in 
the subgroup of patients with schizophrenia a 
positive attitude to pharmacological treatment 
was significantly related to real-world functioning 
change in one year of observation. So, in the 
group of patients with schizophrenia a better 
attitude and adherence to antipsychotic treatment 
recommended by major guidelines produced 
a more pronounced effect (that reached the 
statistical significance) on improvement of real-
life functioning. This result is concordant with 
data from Mohr and colleagues [59], who found 
that functional performances correlated positively 
with subjective satisfaction with medications 
and, in particular, the best level of functioning 
was linked to treatment with antipsychotics. In 
another investigation comparing schizophrenic 
responder, schizophrenic resistant and non-
schizophrenic patients, authors concluded that 
poor adherence to drug therapy may predict poor 
psychosocial functioning in both subgroups of 
schizophrenic patients [60]. Adherence to drug 
therapy, at least in patients with schizophrenia, 
appears a more important factor to change real-
world functioning than drug treatment itself, as 
administration of different classes of drugs was 
never found significant in regression analyses.
This study suffered from some limits. A 
few demographical and clinical data were 
retrospectively collected due to the naturalistic 
design of this study. We did not use specific 
psychopathological rating scales for each 
diagnostic category, but the same clinical global 
impression measure for all the diagnoses. So, we 
cannot determine whether specific clusters of 
symptoms influenced the real-world functioning 
change. There may be additional clinical 
predictors that were not considered in our 
sample and that may play an important role in 
patients’ long-term functional outcome. Despite 
these limitations, there are some strengths of our 
investigation that should be noticed: the large 
number of patients and the naturalistic design 
that avoids the selection biases of randomized 
controlled designs. Indeed, since data from 
randomized controlled trials provide outcome 
measures in a relatively homogenous population 
under artificial conditions, it is important to 
verify these results in real-world settings.
In summary, our naturalistic study was aimed to 
identify in a large sample of outpatients, including 
subjects with schizophrenia, bipolar disorders, 
major depressive disorder, and borderline 
personality disorder, whether demographic and 
clinical variables predict a change in the real-world 
functioning. We found that in the whole sample 
and in each diagnostic category, except for BPD, 
a higher degree of global symptoms was inversely 
related to the change of PSP score and predicted 
a worse community functioning. A history of 
suicide attempts was also associated to reduce 
functioning improvement in the total sample 
and in depressed patients. In each diagnostic 
category, except in BPD, a better subjective 
perception of quality of life was related to the 
change of the dependent variable. Patients with 
major depressive disorder and with borderline 
personality disorder that received interpersonal 
psychotherapy (IPT) showed a higher degree 
of functional improvement. A positive attitude 
and adherence to pharmacological treatment was 
significantly related to the real-world functioning 
improvement only in schizophrenia, but not in 
the other subgroups. Further studies aimed to 
identify predictors of real-world functioning in 
samples of patients with psychiatric disorders are 
required to replicate our findings. Data on this 
topic can be useful to promote a more accurate 
evaluation of patients in order to obtain a better 
functional outcome.
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